Overview: 5-Hydroxy-Indole-Acetic Acid TestIntroduction: The 5-Hydroxy-Indole-Acetic Acid Test measures 5-HIAA, a serotonin metabolite, to detect carcinoid tumors, which cause flushing, diarrhea, or breathing difficulties. Aligned with 2023 North American Neuroendocrine Tumor Society (NANETS) guidelines, it uses chromatography for high sensitivity, enabling accurate diagnosis of neuroendocrine tumors. This test is critical for confirming carcinoid syndrome, guiding surgical or medical therapy (e.g., somatostatin analogs), and monitoring tumor activity, improving outcomes in oncology.
Other Names: 5-HIAA Assay, 5-Hydroxyindoleacetic Acid Test.
FDA Status: Laboratory-developed test (LDT), meeting clinical pathology standards.
Historical Milestone: 5-HIAA was linked to carcinoid tumors in the 1950s. Chromatography-based testing emerged in the 1970s, and by the 2000s, liquid chromatography-mass spectrometry (LC-MS) enhanced specificity for tumor diagnosis.
Purpose: Diagnoses carcinoid tumors, guides therapy, and monitors tumor activity in patients with neuroendocrine symptoms like flushing or diarrhea.
Test Parameters: 1. 5-Hydroxy Indole Acetic Acid
Pretest Condition: No fasting required. Collect urine or plasma at symptom onset. Avoid serotonin-rich foods (e.g., bananas, avocados) for 48 hours to prevent false positives.
Specimen: 5-20 mL urine (sterile container) or 2-4 mL plasma (EDTA). Transport in a biohazard bag within 2 hours, protected from light to prevent degradation.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen, as 5-HIAA may degrade.
Medical History: Document flushing, diarrhea, breathing difficulties, or family history of neuroendocrine tumors. Include medications affecting serotonin levels.
Consent: Written consent is required, explaining the test's purpose, diagnostic implications, and potential therapy needs.
Procedural Considerations: Employs chromatography (LC-MS) to measure 5-HIAA levels. Results are available in 1-2 days, facilitating rapid diagnosis.
Factors Affecting Result Accuracy: Serotonin-rich foods or medications (e.g., SSRIs) may elevate 5-HIAA, causing false positives. Improper storage can degrade samples, affecting accuracy.
Clinical Significance: Elevated 5-HIAA levels confirm carcinoid tumors, prompting imaging or therapy. Normal levels may require chromogranin A or imaging tests for diagnosis.
Specialist Consultation: Consult an oncologist or endocrinologist for result interpretation. Genetic counseling may be advised for familial neuroendocrine tumors.
Additional Supporting Tests: Chromogranin A, CT/MRI, or octreotide scan to confirm carcinoid tumors or assess metastasis.
Test Limitations: False positives may occur with dietary interference. Non-secretory tumors may not be detected.
References: NANETS Guidelines, 2023; Modlin IM, Annals of Oncology, 2022.
